Iino S
Department of Internal Medicine, Division of Gastroenterology & Hepatology, St. Marianna University School of Medicine, Kawasaki 216-8511.
Rinsho Byori. 2001 Aug;49(8):747-54.
Japan has over 2 million patients infected with HCV and is currently facing a crisis of rapid increase in the number of patients with HCV-related liver cirrhosis and hepatocellular carcinoma. To overcome this situation, reliance is placed mainly on IFN therapy with the addition of various therapies to treat symptoms. The knowledge gained to date with IFN monotherapy and the expectations for efficacy to be achieved with IFN + ribavirin combination therapy have been presented.
日本有超过200万丙型肝炎病毒（HCV）感染者，目前正面临着与HCV相关的肝硬化和肝细胞癌患者数量迅速增加的危机。为克服这种情况，主要依靠干扰素治疗，并辅以各种对症治疗。本文介绍了迄今为止干扰素单药治疗所获得的知识以及对干扰素加利巴韦林联合治疗疗效的期望。
